March 5 (Reuters) - Healius' (HLS) shares jumped more than 11% on Tuesday after the healthcare firm said it would start a review and engage investment advisers after Australia's competition regulator killed the $1 billion takeover by rival Australian Clinical Labs (ACL) last year.
Healius also said Chief Financial Officer Paul Anderson will transition to the CEO role, replacing Maxine Jaquet.
News: ACL Australia's Healius jumps on review, CEO change
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.60 |
Change
-0.030(1.14%) |
Mkt cap ! $510.6M | |||
| Open | High | Low | Value | Volume |
| $2.64 | $2.65 | $2.59 | $901.1K | 345.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18300 | $2.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.62 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2025 (20 minute delay) ? |
| ACL (ASX) Chart |